{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 37,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a pyramid/staircase diagram to show progression of clinical advantages.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/8",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.5,
        "x": 0.45,
        "y": 0.13
      },
      "kind": "diagram",
      "text": "Pyramid showing clinical advantages and progression",
      "attrs": null,
      "subkind": "pyramid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8b44647-56ff-4da7-ac7d-70f425e006de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "image",
      "text": "Amgen, Daiichi-Sankyo, CG Oncology logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca5cd10d-ea1d-48fa-b593-4bdb2df1fcc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "list",
      "text": "Limitations of 1st Gen Viruses: Commercial/Late-stage 1st Generation viruses confirm modality's potential; Limited to local delivery and scope of addressable cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d32f5a07-bbc1-4707-b3c3-f8eeac0b4261",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.46,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Clinical Advantages of Olvi-Vec: Systemic Dosing, Target & Treat Metastatic Diseases, Robust Immune Activation, Broad spectrum, Multiple Routes, Tumor Selectivity, Strong immune activator, Nonhuman Pathogen",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53f28e1d-dd90-4bd9-bf5e-5d2ad7a95e65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "A Maturing Modality with Phase 3 Companies validating OV Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f5471a0-671c-47c9-ba96-c321630c6103",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "maturity-model",
      "slug": null,
      "matchId": "3a2958dc-43c3-4d58-a3f9-19b37fdef765",
      "evidence": "Pyramid structure showing progression of clinical validation",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}